A study evaluating clinical outcomes of nintedanib plus docetaxel for refractory non small cell lung cancer patients: Retrospective analysis of korean nintedanib named patient usage program (KCSG LU14-2).
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Docetaxel (Primary) ; Nintedanib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Oct 2017 Results assessing tolerability and clinical activity, presented at the 18th World Conference on Lung Cancer.
- 16 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology